New York State Common Retirement Fund raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 235,878 shares of the company’s stock after purchasing an additional 2,799 shares during the period. New York State Common Retirement Fund owned 0.35% of Myriad Genetics worth $6,095,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of MYGN. Bank of New York Mellon Corp lifted its holdings in Myriad Genetics by 131.2% during the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after purchasing an additional 521,146 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in Myriad Genetics by 45.0% during the first quarter. UBS Asset Management Americas Inc. now owns 34,364 shares of the company’s stock valued at $660,000 after purchasing an additional 10,667 shares in the last quarter. Karp Capital Management Corp purchased a new position in Myriad Genetics during the first quarter valued at $223,000. Ameriprise Financial Inc. purchased a new position in Myriad Genetics during the first quarter valued at $6,992,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in Myriad Genetics by 126.1% during the first quarter. Parametric Portfolio Associates LLC now owns 254,623 shares of the company’s stock valued at $4,889,000 after purchasing an additional 141,993 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Myriad Genetics, Inc. (MYGN) Holdings Boosted by New York State Common Retirement Fund” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/14/myriad-genetics-inc-mygn-holdings-boosted-by-new-york-state-common-retirement-fund.html.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the transaction, the director now directly owns 52,524 shares in the company, valued at approximately $1,591,477.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.20% of the stock is currently owned by corporate insiders.

Myriad Genetics, Inc. (NASDAQ MYGN) opened at 36.44 on Friday. Myriad Genetics, Inc. has a 1-year low of $15.15 and a 1-year high of $37.30. The stock has a market capitalization of $2.49 billion, a P/E ratio of 114.23 and a beta of 0.28. The stock has a 50 day moving average of $33.76 and a 200 day moving average of $25.56.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.36 EPS. On average, analysts expect that Myriad Genetics, Inc. will post $1.03 earnings per share for the current year.

Several research firms have issued reports on MYGN. Morgan Stanley reaffirmed an “underweight” rating and set a $24.00 price objective (up from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Leerink Swann reaffirmed a “market perform” rating and set a $31.00 price objective on shares of Myriad Genetics in a report on Monday, October 2nd. Stephens reaffirmed an “overweight” rating and set a $40.00 price objective (up from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Cowen and Company reaffirmed a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Sunday, September 17th. Finally, Deutsche Bank AG raised shares of Myriad Genetics from a “sell” rating to a “hold” rating and decreased their price objective for the company from $27.86 to $15.00 in a report on Friday, August 18th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $25.00.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.